Tirzepatide for PCOS and weight in women
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests if tirzepatide (a once-weekly injection) can improve periods and metabolic health in women with PCOS who are overweight. If you have PCOS, irregular cycles, and a BMI of 27 or higher, you might qualify.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18–45 with PCOS (diagnosed by a doctor) and have irregular periods or fewer than 8 periods a year.
- Your BMI is 27 or higher (overweight or obese).
- You are not pregnant, not planning pregnancy, and not breastfeeding during the 72-week study.
- You have not used GLP-1 weight-loss drugs (like Wegovy) or diabetes medications (like insulin) in the past 6 months.
- You are willing to stop hormonal birth control (like the pill) and use barrier methods (like condoms) for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the medicine tirzepatide works in real life for adults who are overweight (BMI 30 or more) and have prediabetes or type 2 diabetes. It aims to see if the medicine helps control blood sugar and weight, and it's important that you have had a recent eye exam before starting.
This trial looks at whether a medicine called tirzepatide (given as an injection) helps people with obesity lose weight in real life. Researchers will also see how people use the medicine, which may help doctors find better ways to treat obesity.
This trial tests whether tirzepatide, a weekly injection that helps with weight loss and blood sugar control, can improve outcomes for women with obesity and early-stage endometrial cancer (or precancerous changes) who are scheduled for surgery. The goal is to see if taking this medication before surgery can help shrink the cancer or improve surgical results.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This study tests the diabetes/weight-loss drug tirzepatide (Mounjaro) in young adults aged 18–26 who have obesity and either Prader-Willi syndrome, hypothalamic obesity, or general obesity. It looks at whether a weekly injection can help with weight management.
Hear when a new Polycystic Ovary Syndrome (PCOS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.